Abstract Library

#4557 miR-1290 and miR-320c regulate cell proliferation and predict patient prognosis in neuroendocrine carcinomas

Introduction: The biology of neuroendocrine carcinomas (NECs) remains largely unknown, limiting the use of biomarkers for patient stratification and therapy response prediction in clinical practice.

Conference:

Presenting Author: Liverani C

Authors: Liverani C, Sgolacchia F, Bongiovanni A, Calabrese C, Vanni S,

Keywords: biomarker, miRNAs, neuroendocrine carcinoma,

#3980 Interest of serum and urinary 5HIAA, serotonin, chromogranin A and NT-proBNP assays as predictive factors for the development of carcinoid heart disease in neuroendocrine tumors

Introduction: Carcinoid heart disease (CHD) is the main complication of carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs) and has a poor prognosis, with treatment based mainly on high-risk valve replacement surgery.

Conference:

Presenting Author: Walter T

Authors: Lecoeur A, Sfeir R, Damour J, Lombard-Bohas C, Gerard L,

Keywords: neuroendocrine tumors, carcinoid syndrome, carcinoid heart disease, serum 5HIAA, urinary 5HIAA, serotonin, chromogranin A, NT-proBNP,

#3194 miR-223 - A potential diagnostic biomarker in gastroenteropancreatic neuroendocrine tumors

Introduction: MicroRNAs (miRNAs) are key regulators of tumor biology, with functions that range from an oncogene to a tumor suppressor. They are proposed as diagnostic, prognostic and predictive circulating or tissue-based biomarkers in several human diseases, especially carcinoma. However, their role in pathogenesis of neuroendocrine neoplasia remains incompletely elucidated, and emerging insights still await translation into clinical treatment modalities.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Özdirik B, Mohr R, Geisler L, Tacke F, Jann H,

Keywords: miR-21, miR-223, gastroenteropancreatic, neuroendocrine tumor, diagnostic, biomarker,

#1770 Cytokines as Predictive Factors of Response to Somatostatin Analogues in Patients with Neuroendocrine Tumour

Introduction: The somatostatin analogues are a major therapeutic advance in neuroendocrine tumor (NET) treatment and have multiple modulatory effects on the immune system.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Sciammarella C

Authors: Sciammarella C, Grimaldi A, Circelli L, Modica R, Pizza G,

Keywords: cytokines, neuroendocrine, cell,

#1412 MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease

Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Giandomenico V

Authors: Giandomenico V, Li S, Lind T, Boccherini M, Skogseid B,

Keywords: glycolytic metabolism, peptide receptor radionuclide therapy (PRRT), serum samples, miRNA, FDG-PET positive and-PET negative SI-NET patients,